- Home
- LNKB vs EPIX Comparison
LNKB vs EPIX Comparison
Compare LNKB & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- EPIX
- Stock Information
- Founded
- LNKB 2018
- EPIX 2009
- Country
- LNKB United States
- EPIX Canada
- Employees
- LNKB N/A
- EPIX N/A
- Industry
- LNKB
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- EPIX Health Care
- Exchange
- LNKB Nasdaq
- EPIX Nasdaq
- Market Cap
- LNKB 236.7M
- EPIX 209.4M
- IPO Year
- LNKB N/A
- EPIX N/A
- Fundamental
- Price
- LNKB $6.54
- EPIX $5.77
- Analyst Decision
- LNKB Hold
- EPIX Buy
- Analyst Count
- LNKB 1
- EPIX 2
- Target Price
- LNKB $7.50
- EPIX $17.00
- AVG Volume (30 Days)
- LNKB 40.5K
- EPIX 41.5K
- Earning Date
- LNKB 10-25-2024
- EPIX 12-10-2024
- Dividend Yield
- LNKB 4.53%
- EPIX N/A
- EPS Growth
- LNKB N/A
- EPIX N/A
- EPS
- LNKB N/A
- EPIX N/A
- Revenue
- LNKB $68,142,000.00
- EPIX N/A
- Revenue This Year
- LNKB N/A
- EPIX N/A
- Revenue Next Year
- LNKB $4.03
- EPIX N/A
- P/E Ratio
- LNKB N/A
- EPIX N/A
- Revenue Growth
- LNKB 101.22
- EPIX N/A
- 52 Week Low
- LNKB $5.86
- EPIX $3.80
- 52 Week High
- LNKB $8.29
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- LNKB 55.81
- EPIX 45.92
- Support Level
- LNKB $6.36
- EPIX $5.68
- Resistance Level
- LNKB $6.68
- EPIX $6.24
- Average True Range (ATR)
- LNKB 0.15
- EPIX 0.47
- MACD
- LNKB 0.03
- EPIX -0.04
- Stochastic Oscillator
- LNKB 73.08
- EPIX 14.58
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.